ClinVar Miner

Submissions for variant NM_014244.5(ADAMTS2):c.3625G>A (p.Gly1209Arg)

gnomAD frequency: 0.00001  dbSNP: rs769813298
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000492950 SCV000582518 uncertain significance not provided 2017-05-10 criteria provided, single submitter clinical testing A variant of uncertain significance has been identified in the ADAMTS2 gene. The G1209R variant has not been published as pathogenic or been reported as benign to our knowledge. G1209R is not observed at a significant frequency in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The G1209R variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. However, this substitution occurs at a position that is not conserved, where R1209 is the wild-type amino acid residue in multiple species. In silico analysis predicts this variant likely does not alter the protein structure/function. Furthermore, no missense variants in nearby residues have been reported in the Human Gene Mutation Database in association with EDS (Stenson et al., 2014).
Invitae RCV001834600 SCV003254589 uncertain significance Ehlers-Danlos syndrome, dermatosparaxis type 2022-08-22 criteria provided, single submitter clinical testing This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 1209 of the ADAMTS2 protein (p.Gly1209Arg). This variant is present in population databases (rs769813298, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with ADAMTS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 429851). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Natera, Inc. RCV001834600 SCV002081874 uncertain significance Ehlers-Danlos syndrome, dermatosparaxis type 2019-10-28 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.